A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

Inclusion Criteria: 1. Signed informed consent form before any trial-related processes; 2. Age ≥18 years; 3. Histologically or cytologically confirmed ES-SCLC; 4. No prior systemic therapy for ES-SCLC; 5. Have adequate organ function; 6. The Eastern Cancer Cooperative Group (ECOG) performance score of 0 or 1; 7. Life expectancy of ≥12 weeks; 8. Had at least one measurable tumor lesion according to RECIST v1.1. Exclusion Criteria: 1. Histologically or cytologically confirmed mixed SCLC; 2. History of severe allergic disease, severe drug allergy or have known allergy to any component of the study drugs; 3. The toxicity of previous anti-tumor therapy has not been alleviated； 4. Have received anti-platelet therapy within 10 days prior to the first dose of the study drugs; 5. Evidence and history of severe bleeding tendency; 6. History of severe cardiovascular diseases within 6 months; 7. Current presence of uncontrolled pleural, pericardial, and peritoneal effusions; 8. History of allogeneic hematopoietic stem cell transplantation or allogeneic organ transplantation; 9. History of alcohol abuse, psychotropic substance abuse or drug abuse; 10. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome; 11. Pregnant or lactating women; 12. Other conditions considered unsuitable for this study by the investigator.